Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

Table 3 BiTes currently in FL trials

BiTe	NCT#/publication	Route/Administration schedule	Phase	Total n [FL]	Median lines of prior therapy	% POD24	ORR%^a [CR%]	mPFS	CRS % [G ≥ 3]	Neuro % [G ≥ 3]	Approved
Mosunetuzumab	[96]	IV Qweekly for cycle 1, Q21 days for cycles ≥ 2, stopped after cycle 8 for CR	1	62 [62]	3	48	68 [50]	11.8	2	0	–
Odronextumab	[97]	IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36	1	96 [25]	3	NP	93 [71]	NP	7	3	–
Odronextumab	NCT03888105 [98]	IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36	II	NA^b	NA^b	NA^b	NA^b	NA^b	NA^b	NA^b	–
Epcoritamab	[100]	sq Qweekly C1-2, Q2 weeks C3-6, Q4 weeks thereafter, 28 day cycles	I	67 [12]	3	NP	100 [25]	NP	0	3	–
Glofitamab	[108]	Obinutuzumab on D-7, weekly for two weeks then Q2 weeks for 28 weeks	I	171 [44]	3	NP	62 [52]^c	11.8	3.5	1.2	–

Abbreviations: CRS—cytokine release syndrome; CR—complete response rate; Neuro—neurotoxicity; NP—not presented; ORR—overall response rate; PFS—progression-free survival; POD24—progression of disease within 24 months following chemoimmunotherapy; sq—subcutaneous; Qweekly—every week; Q2 weeks—every 2 weeks
^aResponse rates in FL subset
^bNot available, clinical trial is ongoing
^cfor cohorts receiving ≥ 10 mg dosing

ISSN: 1756-8722